Completed PHASE1 INTERVENTIONAL 2-arm NCT05497570

Injection of Tenoxicam Versus Arthrocentesis Alone in the Treatment of Temporomandibular Joint Osteoarthritis

Does Intra-articular Injection of Tenoxicam After Arthrocentesis Heal Outcomes of Temporomandibular Joint Osteoarthritis? A Randomized Clinical Trial

Sponsor: Ataturk University

Conditions Arthrocentesis

Interventions Tenoxicam Injectable Product

Updated 4 times since 2022 Last updated: Aug 10, 2022 Started: May 3, 2019 Primary completion: Nov 7, 2021 Completion: Apr 21, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Arthrocentesis, this trial is completed. The trial is conducted by Ataturk University and has accumulated 4 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2022 — Jul 2024 [monthly]

Completed PHASE1

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ataturk University

Data source: Ataturk University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Erzurum, Turkey (Türkiye)